Publications by authors named "W Mueck"

Claim this Profile
S
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
Michael Boettcher, Dirk Thomas, Wolfgang Mueck, Stephanie Loewen, Erich Arens

Eur J Clin Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
Michael Boettcher, Michael Gerisch, Maximilian Lobmeyer, Nina Besche, Dirk Thomas, Wolfgang Mueck

Clin Pharmacokinet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters, Wolfgang Mueck

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters, Wolfgang Mueck

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Alexander Solms, Matthias Frede, Scott D Berkowitz, Anne Hermanowski-Vosatka, Dagmar Kubitza, Wolfgang Mueck

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis